Navarro-Compán V, Sepriano A, El-Zorkany B, van der Heijde D. Axial spondyloarthritis. Ann Rheum Dis. 2021;80(12):1511–21. https://doi.org/10.1136/annrheumdis-2021-221035.

Article  CAS  PubMed  Google Scholar 

Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017;390(10089):73–84. https://doi.org/10.1016/S0140-6736(16)31591-4.

Article  PubMed  Google Scholar 

Gao X, Wendling D, Botteman MF, Carter JA, Rao S, Cifaldi M. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents. J Med Econ. 2012;15(6):1054–63. https://doi.org/10.3111/13696998.2012.692341.

Article  PubMed  Google Scholar 

Stolwijk C, van Onna M, Boonen A, van Tubergen A. Global prevalence of spondyloarthritis: a systematic review and meta-regression analysis. Arthritis Care Res (Hoboken). 2016;68(9):1320–31. https://doi.org/10.1002/acr.22831.

Article  PubMed  Google Scholar 

Zhang S, Peng L, Li Q, Zhao J, Xu D, Zhao J, et al. Spectrum of spondyloarthritis among Chinese populations. Curr Rheumatol Rep. 2022;24(8):247–58. https://doi.org/10.1007/s11926-022-01079-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boonen A, van der Linden SM. The burden of ankylosing spondylitis. J Rheumatol Suppl. 2006;78:4–11.

PubMed  Google Scholar 

Yurdakul OV, Ince OE, Bagcier F, Kara M, Kultur E, Aydin T. Evaluating the strength of spinal and proximal girdle muscles in patients with axial spondyloarthritis: correlation with activity, disability, and functionality. Int J Rheum Dis. 2021;24(5):701–10. https://doi.org/10.1111/1756-185x.14102.

Article  PubMed  Google Scholar 

Tam LS, Wei JC, Aggarwal A, Baek HJ, Cheung PP, Chiowchanwisawakit P, et al. 2018 APLAR axial spondyloarthritis treatment recommendations. Int J Rheum Dis. 2019;22(3):340–56. https://doi.org/10.1111/1756-185x.13510.

Article  PubMed  Google Scholar 

Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2019;71(10):1599–613. https://doi.org/10.1002/art.41042.

Article  PubMed  PubMed Central  Google Scholar 

Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82(1):19–34. https://doi.org/10.1136/ard-2022-223296.

Article  PubMed  Google Scholar 

Fragoulis GE, Siebert S. Treatment strategies in axial spondyloarthritis: what, when and how? Rheumatol (Oxf). 2020;59(Suppl 4):79–89. https://doi.org/10.1093/rheumatology/keaa435.

Article  CAS  Google Scholar 

Sepriano A, Regel A, van der Heijde D, Braun J, Baraliakos X, Landewé R, et al. Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. RMD Open. 2017;3(1):e000396. https://doi.org/10.1136/rmdopen-2016-000396.

Article  PubMed  PubMed Central  Google Scholar 

D’Angelo S, Carriero A, Gilio M, Ursini F, Leccese P, Palazzi C. Safety of treatment options for spondyloarthritis: a narrative review. Expert Opin Drug Saf. 2018;17(5):475–86. https://doi.org/10.1080/14740338.2018.1448785.

Article  CAS  PubMed  Google Scholar 

Eli Lilly and Company: Taltz 80 mg (ixekizumab) solution for injection in pre-filled syringe. Summary of medical product characteristics. 2022. https://www.ema.europa.eu/documents/product-information/taltz-epar-product-information_en.pdf. Accessed Dec 2022.

Eli Lilly and Company: TALTZ (ixekizumab) injection, for subcutaneous use. Prescribing information. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125521s004lbl.pdf. Accessed Dec 2022.

Dougados M, Wei JC, Landewé R, Sieper J, Baraliakos X, Van den Bosch F, et al. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Ann Rheum Dis. 2020;79(2):176–85. https://doi.org/10.1136/annrheumdis-2019-216118.

Article  CAS  PubMed  Google Scholar 

van der Heijde D, Cheng-Chung Wei J, Dougados M, Mease P, Deodhar A, Maksymowych WP, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying antirheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018;392(10163):2441–51. https://doi.org/10.1016/s0140-6736(18)31946-9.

Article  CAS  PubMed  Google Scholar 

Deodhar A, Poddubnyy D, Pacheco-Tena C, Salvarani C, Lespessailles E, Rahman P, et al. Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors. Arthritis Rheumatol. 2019;71(4):599–611. https://doi.org/10.1002/art.40753.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–51. https://doi.org/10.1016/S0140-6736(15)60125-8.

Article  CAS  PubMed  Google Scholar 

Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumor necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017;389(10086):2317–27. https://doi.org/10.1016/S0140-6736(17)31429-0.

Article  CAS  PubMed  Google Scholar 

Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79–87. https://doi.org/10.1136/annrheumdis-2016-209709.

Article  CAS  PubMed  Google Scholar 

Deodhar A, Poddubnyy D, Rahman P, Ermann J, Tomita T, Bolce R, et al. Long-term safety and efficacy of ixekizumab in patients with axial spondyloarthritis: 3-year data from the COAST program. J Rheumatol. 2023. https://doi.org/10.3899/jrheum.221022.

Article  PubMed  Google Scholar 

Ixekizumab_Chinese_PI. Ixekizumab Chinese prescribing information. 2023. https://www.lillymedical.cn/books/%E4%BE%9D%E5%A5%87%E7%8F%A0%E5%8D%95%E6%8A%97%E6%B3%A8%E5%B0%84%E6%B6%B2%E8%AF%B4%E6%98%8E%E4%B9%A6.pdf. Accessed Jan 2023.

van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361–8. https://doi.org/10.1002/art.1780270401.

Article  PubMed  Google Scholar 

Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68(Suppl 2):1–44. https://doi.org/10.1136/ard.2008.104018.

Article  Google Scholar 

Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286–91.

CAS  PubMed  Google Scholar 

Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum. 2001;44(8):1876–86. https://doi.org/10.1002/1529-0131(200108)44:8%3c1876::Aid-art326%3e3.0.Co;2-f.

Article  CAS  PubMed  Google Scholar 

Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J. Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Ann Rheum Dis. 2004;63(11):1438–44. https://doi.org/10.1136/ard.2003.016717.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Machado PM, Landewé R, Heijde DV. Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states. Ann Rheum Dis. 2018;77(10):1539–40. https://doi.org/10.1136/annrheumdis-2018-213184.

Article  PubMed  Google Scholar 

Calin A, Jones SD, Garrett SL, Kennedy LG. Bath ankylosing spondylitis functional index. Br J Rheumatol. 1995;34(8):793–4. https://doi.org/10.1093/rheumatology/34.8.793.

Article  CAS  PubMed  Google Scholar 

Maksymowych WP, Inman RD, Salonen D, Dhillon SS, Krishnananthan R, Stone M, et al. Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of spinal inflammation in ankylosing spondylitis. Arthritis Rheum. 2005;53(4):502–9. https://doi.org/10.1002/art.21337.

Article  PubMed  Google Scholar 

Zochling J. Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), and Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S47-58. https://doi.org/10.1002/acr.20575.

Article  PubMed  Google Scholar 

Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003;48(11):3230–6. https://doi.org/10.1002/art.11325.

Article  CAS  PubMed  Google Scholar 

Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52(10):3279–89. https://doi.org/10.1002/art.21306.

Article  CAS  PubMed